A policy statement released this month by the European Association for the Study of the Liver (EASL) formally addresses the pervasive stigma surrounding liver disease and its impact on patient care across Europe. The statement, published in June 2025, outlines strategies to combat discrimination and improve healthcare access for individuals affected by liver conditions.
The move comes as public health concerns related to liver diseases gain prominence, highlighted at recent medical congresses. Experts are increasingly recognizing that stigma significantly hinders both the management and treatment outcomes for patients. This stigmatization often stems from misconceptions and a tendency to blame individuals for their condition, particularly when linked to lifestyle factors.
The stigma associated with liver disease is particularly acute for women, according to a recent article by the European Public Health Alliance. Social norms often impose harsher judgment on women diagnosed with conditions like cirrhosis or hepatitis, especially if those conditions are linked to alcohol consumption. This bias can lead to self-stigma, delayed diagnosis, and reduced engagement with healthcare services.
Beyond societal perceptions, systemic biases within the healthcare system also contribute to inequities. Women are underrepresented in clinical trials for liver cancer, despite a rising incidence of the disease in this population. Individuals who inject drugs and contract Hepatitis C, particularly women, are less likely to receive potentially curative direct-acting antiviral treatments. Current medical scoring systems used to assess liver disease severity have been shown to underestimate the condition’s impact on women, potentially reducing their chances of receiving life-saving liver transplants.
A recent study involving over 2,100 patients with nonalcoholic fatty liver disease (NAFLD) from 24 countries revealed that nearly a quarter reported experiencing stigma due to obesity, and 9% due to NAFLD itself. The study, published in JHEP Reports, found that patients who reported stigmatization experienced significantly lower health-related quality of life scores. Importantly, the experience of stigmatization was identified as the strongest independent predictor of lower quality of life, even more impactful than the disease itself.
The study also highlighted the role of self-blame in the disease burden experienced by patients. Participants who reported stigmatization due to obesity also reported lower scores in areas such as activity levels, emotional health, and fatigue. Discomfort with the term “fatty liver disease” was also linked to lower emotional health scores.
The EASL policy statement aims to address these issues by promoting equitable healthcare access and enhancing patient outcomes. The statement’s specific strategies have not been publicly detailed, but the organization’s commitment signals a growing recognition of the need to dismantle the barriers created by stigma and discrimination within the field of hepatology. The Global NASH Council is continuing to assess the burden of liver disease and the relationship between stigma and quality of life.
